Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02016781

Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.

Status: 
Recruiting
Study Date: 
Sun, 12/01/2013 to Thu, 12/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Procedure: Allogeneic Hematopoietic Cell Transplant Bone marrow or peripheral blood stem cell transplant. The specific transplant treatment regimen will be at the discretion of the treating physician. Other Name: RIC alloHCT Procedure: Hypomethylating Therapy / Best Supportive Care The specific non-transplant treatment regimen will be at the discretion of the treating physician. Other Name: Non-transplant